We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

The relation between TORC1 and TORC2 expression and response on mTOR inhibitors treatment in uterine sarcoma and carcinosarcoma cell lines

Submitted

and 3 other(s)

34 Views
0 Downloads
0 Saves

Presented at

ESGO State of the Art 2018 Conference

-

Presentation

thumbnail

Abstract

Introduction mTOR inhibitors (mTORi) is one of the most promising group of anticancer agents considered to be active against uterine mesenchymal malignancies. A few recently published trials revealed its activity but in most of them only a part of patients responded to the treatment. No biomarkers allowing to assess the response to mTOR inhibitors were identified so far. Taking into consideration the mechanisms of intracellular activity of first (rapamycin) and second (INK 128) generation of mTORi, targeting TORC1 and both TORC1 and TORC2, respectively, we aimed to assess the expression of mentioned mTOR complexes in selected uterine sarcoma and carcinosarcoma cell lines and analyze its relation to the response to rapamycin and INK 128 treatment. Materials and methods Four cell lines derived from uterine leiomyosarcoma (MES-SA), endometrial stromal sarcoma (ESS-1), carcinosarcoma (SKUT-1, SKUT1B) were selected to be used in the study, the control normal line was HSF (human skin fibroblasts). Cell from cultures were harvested and used to prepare paraffin embaded slides. The expression of TORC1 and TORC 2 was visualized using immunochemistry according to antibody manufacturer recommendations and assessed by semiquantitive method as no expression/weak expression/strong expression/very strong expression. To reveal the response to mTORi treatment, cells were cultured in presence of rapamycin in concentrations 0,25–2500 ng/ml and INK128 in concentrations 0,1–100 ng/ml for 96 h. Cell viability was assessed using MTT test. The response of cell lines were expressed as IC50 value. Results Very strong expression of TORC1 was detected in MES-SA cell line, weak In SKUT-1 and SKUT-1B, no expression was found in HSF an ESS-1 lines. The expression of TORC2 was considered as very strong in MES-SA cell line, as weak In HSF, SKUT1, SKUT-1 and ESS-1. IC50 for rapamycin was achievable for ESS-1 and MES-SA and valued 661,6 ng/ml and 1,1 ng/ml respectively. For INK 128 it was measured for SKUT-1, SKUT1B, ESS-1 and MES-SA the values were figured as 214,2 ng/ml, 78,8 ng/ml, 18,7 ng/ml and 3,7 ng/ml respectively Conclusion Our data shows that very strong expression of TORC complexes is related to good response to mTORi as it was observed In leiomyosarcoma cell line. We noted that endometrial stromal sarcoma cell line presented some sensitivity for rapamycin in spite of no expression of TROC1, this finding can be explained by limited sensitivity of imunochemistry, it is worth to point out that IC50 value was over 600 times higher comparing to leiomyosarcoma cell line response. Weak expression of both TORC complexes in carcinosarcoma cell lines correspond with relatively high concentration of INK 128 necessary to achieve half maximal inhibition of cells viability. Interestingly we do not observed significant impact of tested substances on normal cells (human skin fibroblasts) in concentrations that were sufficient to affect the most sensitive cancer cell lines.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.